Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Member Login Email Password Join Now Forgotten Password Newsletters/Portfolios View Current and Archived Dividend Growth Newsletters View Current and Archived Best Ideas Newsletters Valuentum's Dividend Growth Newsletter Portfolio Valuentum's Best Ideas Newsletter Portfolio Order the Exclusive Publication! View Current and Archived Exclusive Editions Order the High Yield Dividend Newsletter! Dividend Cushion Efficacy Calculation Dividend-Adjusted Leverage White Paper Stock Screens How to Filter Data in Microsoft Excel Like a Pro Download Weekly Stock Screener (xls) -- login required The Quarterly DataScreener Products & Tools Financial Advisor (GOLD LEVEL) Publications DCF Valuation Model Template Order Value Trap Order Value Trap, second edition Value Trap Order PDF Copy Order Paperback Copy Presentation BookLife Review BlueInk Review Foreword Review Readers' Favorite Review Axiom Bronze Praise The Buying Index, VBI Value and Momentum Within Stocks, Too (2017) The Case for the Valuentum Style of Investing (2012) Investing's Odd Couple: Value and Momentum (2013) Stock-Selection Methodology, the Valuentum Buying Index (2011) Why Valuentum Buying Index Ratings Matter (2014) Dividend Changes Dividend Increases/Decreases for the Week of April 5 Dividend Increases/Decreases for the Week of March 29 Dividend Increases/Decreases for the Week of March 22 Dividend Increases/Decreases for the Week of March 15 Dividend Increases/Decreases for the Week of March 8

Results 51 - 60 of 201 for hum. (0.31 seconds) Amgen’s Second Quarter Doesn’t Disappoint Amgen posted a solid second quarter, but we think shares... LinkedIn’s Powerful Network Drives Strong Results LinkedIn continues to execute on revenue growth... Strength in Footwear Persists DSW ups its 2013 forecast on better-than-anticipated... LinkedIn Acknowledges Its Stock Is Overpriced LinkedIn will offer $1.2 billion worth of stock at a... Banks Pass Self-Administered Stress Tests Not surprisingly, the “too big to fail” banks... Arena Pharmaceuticals' Belviq Approval May Not Match The Hype We think Arena Pharma has too much risk. How We're Prepared for the Debt Ceiling Deadline There are no surprises here… Surveying 3Q Performance from Big Pharma: Bristol-Myers, Eli Lilly, and AbbVie Let’s take a look at the third-quarter performance... LinkedIn’s Growth Doesn’t Disappoint But Its Valuation Is Absurd LinkedIn’s top-line expansion remains fantastic,... Twitter Prices at $45.10 Per Share, Up 70%+ From $26 IPO Price We think Twitter will steal the news headlines in coming... prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | next